ADCs or: How I Learned to Stop Worrying and Love Chemotherapy
- PMID: 37009702
- DOI: 10.1158/2159-8290.CD-23-0091
ADCs or: How I Learned to Stop Worrying and Love Chemotherapy
Abstract
Antibody-drug conjugates are transforming cancer treatment, and payload characteristics are emerging as crucial determinants of clinical activity. As exemplified by Weng and colleagues, advancements in the linker and payload chemistry may provide the next evolutionary step in enabling this class of drugs to overcome chemoresistance and deliver even more profound responses. See related article by Weng et al., p. 950 (2).
©2023 American Association for Cancer Research.
Comment on
-
Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer.Cancer Discov. 2023 Apr 3;13(4):950-973. doi: 10.1158/2159-8290.CD-22-1368. Cancer Discov. 2023. PMID: 36693125
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
